JP4463554B2 - 短い二本鎖RNAのinvitro合成方法 - Google Patents
短い二本鎖RNAのinvitro合成方法 Download PDFInfo
- Publication number
- JP4463554B2 JP4463554B2 JP2003542541A JP2003542541A JP4463554B2 JP 4463554 B2 JP4463554 B2 JP 4463554B2 JP 2003542541 A JP2003542541 A JP 2003542541A JP 2003542541 A JP2003542541 A JP 2003542541A JP 4463554 B2 JP4463554 B2 JP 4463554B2
- Authority
- JP
- Japan
- Prior art keywords
- template
- target
- sequence
- rna polymerase
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims abstract description 109
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims abstract description 44
- 238000000338 in vitro Methods 0.000 title claims abstract description 28
- 238000001308 synthesis method Methods 0.000 title description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 127
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 66
- 108020004414 DNA Proteins 0.000 claims abstract description 26
- 102000053602 DNA Human genes 0.000 claims abstract description 11
- 239000004055 small Interfering RNA Substances 0.000 claims description 115
- 239000002773 nucleotide Substances 0.000 claims description 108
- 125000003729 nucleotide group Chemical group 0.000 claims description 107
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 46
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 46
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 230000000295 complement effect Effects 0.000 claims description 30
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 24
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 239000011541 reaction mixture Substances 0.000 claims description 17
- 108091027075 5S-rRNA precursor Proteins 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 108020004519 Antisense Oligoribonucleotides Proteins 0.000 claims description 15
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 15
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 15
- 239000002825 antisense oligoribonucleotide Substances 0.000 claims description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
- 230000002441 reversible effect Effects 0.000 claims description 9
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 8
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 8
- 229940029575 guanosine Drugs 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- 229940104302 cytosine Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 abstract description 20
- 230000035897 transcription Effects 0.000 abstract description 20
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 230000009368 gene silencing by RNA Effects 0.000 abstract description 16
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 230000032361 posttranscriptional gene silencing Effects 0.000 abstract description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract description 3
- 241001515965 unidentified phage Species 0.000 abstract description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 57
- 230000000694 effects Effects 0.000 description 34
- 239000000047 product Substances 0.000 description 27
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 23
- 239000004970 Chain extender Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 239000005089 Luciferase Substances 0.000 description 14
- 108060001084 Luciferase Proteins 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 6
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 101710178747 Phosphatidate cytidylyltransferase 1 Proteins 0.000 description 5
- 108091028664 Ribonucleotide Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002336 ribonucleotide Substances 0.000 description 5
- 125000002652 ribonucleotide group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100033118 Phosphatidate cytidylyltransferase 1 Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000004712 monophosphates Chemical class 0.000 description 3
- -1 nucleotides Small molecule Chemical class 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000004850 capillary HPLC Methods 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- 102000007528 DNA Polymerase III Human genes 0.000 description 1
- 108010071146 DNA Polymerase III Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101150026109 INSR gene Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 101100018931 Mus musculus Insr gene Proteins 0.000 description 1
- 101000852813 Mus musculus Insulin receptor Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 101150032670 est gene Proteins 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Description
Caplen,N.ら、2001、PNAS(98)9742−9747 Elbashir S.ら、2001、Nature(411)494−498 Milligan F.ら、1987、Nucleic Acid Res.(15)8783−8798
本発明は、a)鋳型で伸長されたセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中でセンスの標的特異的オリゴヌクレオチド鋳型および鎖伸長酵素を組み合わせること;b)鋳型で伸長されたアンチセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中でアンチセンスの標的特異的オリゴヌクレオチド鋳型および鎖伸長酵素を組み合わせること;ならびにc)段階a)で得られるセンスオリゴリボヌクレオチド産物を段階b)で得られる相補的アンチセンスオリゴリボヌクレオチド産物とハイブリダイズさせること、の段階を含んで成る短い二本鎖の標的特異的なRNAのin vitro合成方法を提供する。
本発明は短い二本鎖標的特異的RNAの合成の分野に関し、そして鎖伸長酵素を使用するオリゴヌクレオチド鋳型のin vitro転写に基づく。
1)標的遺伝子のコーディング配列内に配置されかつ以下の配列5’−xx(n12−30)yy−3’[式中xはプロモーターから転写されたヌクレオチドを指し、yはプロモーター配列から転写されたヌクレオチドに相補的なヌクレオチドを指し、そしてn12−30は12ないし30ヌクレオチドのいずれかのオリゴヌクレオチドを指す]を有する標的特異的配列を探す
2)場合によっては2個の付加的なヌクレオチドを伴い伸長された段階1)で配置された標的特異的配列の相補物オリゴヌクレオチド配列を伴い鋳型鎖の5’端で伸長された本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るセンスオリゴヌクレオチド鋳型を設計する。
3)場合によっては2個の付加的なヌクレオチドを伴い伸長された段階1)で配置された標的特異的配列の逆オリゴヌクレオチド配列を伴い鋳型鎖の5’端で伸長された本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るアンチセンスオリゴヌクレオチド鋳型を設計する
を含んで成る。
1)標的遺伝子のコーディング配列内に配置されかつ以下の配列5’−gg(n12−30)cc−3’を有する標的特異的配列を探す;
2)場合によっては2個の付加的なヌクレオチドを伴い伸長された以下の配列
5’TAATACGACTCACTATAGG
3’ATTATGCTGAGTGATATcc(n相補物)12−30gg[式中(n相補物)12−30は段階1)で配置された標的特異的配列の相補物オリゴヌクレオチド配列を指す]を有するセンスオリゴヌクレオチド鋳型を設計する;ならびに
3)場合によっては2個の付加的なヌクレオチドを伴い伸長された以下の配列
5’TAATACGACTCACTATAGG
3’ATTATGCTGAGTGATATcc(n逆)12−30gg[式中(n逆)12−30は段階1)で配置された標的特異的配列の逆オリゴヌクレオチド配列を指す]を有するアンチセンスオリゴヌクレオチド鋳型を設計する
を含むことができる。
1)標的遺伝子のコーディング配列内に配置されかつ以下の配列5’−xx(n15−30)yy−3’[式中xはプロモーターから転写されたヌクレオチドを指し、yはプロモーター配列から転写されたヌクレオチドに相補的なヌクレオチドを指し、そしてn15−30は15ないし30ヌクレオチドのいずれかのオリゴヌクレオチドを指す]を有する標的特異的配列を探す;
2)2個の付加的なヌクレオチド、好ましくは2個のアデニン残基を伴い伸長される段階1)で配置された標的特異的配列の相補物オリゴヌクレオチド配列を伴い鋳型鎖の5’端で伸長された本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るセンスオリゴヌクレオチドsiRNA鋳型を設計する;
3)2個の付加的なヌクレオチド、好ましくは2個のアデニン残基を伴い伸長された段階1)で配置された標的特異的配列の逆オリゴヌクレオチド配列を伴い鋳型鎖の5’端で伸長された本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るアンチセンスオリゴヌクレオチドsiRNA鋳型を設計する
を含むことができる。
1)標的遺伝子のコーディング配列内に配置されかつ以下の配列5’−gg(n15−30)cc−3’を有する標的特異的配列を探す;
2)以下の配列
5’TAATACGACTCACTATAGG
3’ATTATGCTGAGTGATATcc(n相補物)15−30ggaa
[式中(n相補物)15−30は段階1)で配置された標的特異的配列の相補物オリゴヌクレオチド配列を指す]を有するセンスオリゴヌクレオチドsiRNA鋳型を設計する;ならびに
3)以下の配列
5’TAATACGACTCACTATAGG
3’ATTATGCTGAGTGATATcc(n逆)15−30ggaa
[式中(n逆)15−30は段階1)で配置された標的特異的配列の逆オリゴヌクレオチド配列を指す]を有するアンチセンスオリゴヌクレオチドsiRNA鋳型を設計する
を含むことができる。
i)標的特異的センスおよびアンチセンスオリゴヌクレオチド鋳型の設計方法
ii)短い二本鎖RNAのin vitro合成方法での使用のための本発明の鎖伸長酵素
iii)センスおよびアンチセンスオリゴリボヌクレオチド産物を得るための精製手段。
iv)センスおよびアンチセンスオリゴリボヌクレオチド産物が本発明の鎖伸長酵素を使用して標的特異的センスおよびアンチセンス鋳型から形成されるような反応混合物のための試薬
を提供する。
材料および方法
プラスミド構築物
ルシフェラーゼ+はプラスミドpGL3−control(プロメガ(Promega))から発現させた。EGFPは哺乳動物発現ベクターpcDNA5/FRT(インヴィトロジェン(Invitrogen))のHindIIIおよびNotI部位に指向性に(directionally)連結されたpEGFP(クロンテック(Clonetech))からのEGFP遺伝子を含有するEGFP/pcDNA5−FRTから発現させた。
siRNAのin vitro転写およびハイブリダイゼーション
オリゴ鋳型鎖は2分間沸騰させかつ2〜3時間にわたって室温にゆっくり冷却することにより10mMトリス−HCl pH9.0、100mM NaCl、1mM EDTA中でセンスT7 プロモーター配列(5’TAATACGACTCACTATAGG)にハイブリダイズさせた。転写は製造元の説明書に従ってMEGAshortscriptTMT7キット(アンビオン(Ambion))を使用して実施した。siRNA鎖はG−25スピンカラムで精製し、重相ロックゲル(Heavy Phase−Lock Gel)(エッペンドルフ(Eppendorf))を使用してフェノール:クロロホルム:イソアミルアルコール(25:24:1)抽出し、そして−80℃で一夜エタノール沈殿した。相補的siRNA鎖を、2分間煮沸しかつ2〜3時間にわたって室温にゆっくり冷却することにより1mMトリス−HCl pH8.0、1mM EDTA pH8.0中でハイブリダイズさせた。ハイブリダイゼーションは非変性20%ポリアクリルアミドTBEゲル上でds−およびss−siRNAを泳動することにより評価した。
細胞系およびトランスフェクション
HeLa細胞は1.8mM l−グルタミン、9%FBSおよび45U/lペニシリン/ストレプトマイシンで補充した高ブドウ糖およびl−グルタミンを含むDMEM(インヴィトロジェン(Invitrogen))中で成長させた。細胞をElbashirら(2001)に記述されたものに類似の様式でトランスフェクトした。トランスフェクション24時間前に細胞をトリプシン処理しそして抗生物質を欠く成長培地で3×105細胞/mlに希釈した。0.5mlの細胞を24ウェルプレートの各ウェルに接種した。細胞は別の方法で示される場合を除き製造元の説明書に従ってリポフェクタミン[Lipofectamine]TM2000(LF2000;インヴィトロジェン(Invitrogen))を使用して1μgのGL3−controlもしくはEGFP/pcDNA5−FRTレポーター構築物および50pmolの一本鎖もしくは25pmolの二本鎖siRNAでトランスフェクトした。具体的には、われわれは抗生物質を欠く血清を含まない培地48μl中でウェルあたり2μlのLF2000を使用した。希釈されたLF2000を50μlの総容量に同一培地で希釈されたレポーターおよび/もしくはsiRNAと混合する前に1分間室温で前インキュベートした。その後、複合体を細胞に添加する前に20分間室温でインキュベートした。EGFPおよびGL3レポーター遺伝子アッセイを24時間後に実施した。JNK2α1 siRNA実験およびGL3 siRNA用量応答実験に6ウェルプレートを使用した。細胞数を4倍および試薬量を5倍増大させた。JNK2α1 siRNA実験には細胞をRNA単離のため収集し、また、タンパク質抽出はトランスフェクションおよそ48時間後であった。
レポーター遺伝子アッセイ
EGFPでトランスフェクトした細胞のFACSアッセイはFACScan(ベクトン・ディッキンソン(Beckton−Dickinson))を使用して実施した。細胞をトリプシン処理しそしてFACS固定溶液(PBS+1%ホルムアルデヒド)中への再懸濁前にPBSで洗浄した。トランスフェクション効率を、水でトランスフェクトしたサンプルをEGFP/pcDNA5−FRTでトランスフェクトしたものと比較することにより推定し、そして典型的には75〜90%であった。転写されたもしくは合成のsiRNAにより誘導されるRNAiの程度は、コトランスフェクトしたsiRNAを伴うもしくは伴わないサンプル中の平均GFP蛍光の変化から推定した。
ノーザンおよびウェスタンブロッティング
全RNAは製造元の説明書に従ってRNイージーミニキット(RNeasy Mini Kit)(キアゲン(Qiagen))を使用しておよそ106HeLa細胞のサンプルから調製した。サンプルを製造元の説明書に従ってプレキャストMOPSラチチュード(Latitude)RNAアガロースゲル(バイオウイタッカー モレキュラー アプリケーションズ(BioWhittaker Molecular Applications))上で泳動しそしてハイボンド(Hybond)−XLナイロンメンブレン(AP バイオテック(AP Biotech))に転写した。DNAプローブは製造元の説明書に従ってレディプライム(Rediprime)IIシステム(AP バイオテック(AP Biotech))を使用して作成した。ハイブリダイゼーションは製造元の説明書に従ってラピッド−ハイブ(Rapid−Hyb)溶液(AP バイオテック(AP Biotech))中で実施した。
結果
RNAiは2個の3’でオーバーハングするヌクレオチドを除き二本鎖であるsiRNAを使用して以前に立証されている(Elbashirら 2001;Caplenら 2001)。複数の細胞標的に対する多様なsiRNAを比較的迅速かつ安価に創製するために、われわれはin vitro転写技術を使用して分子を生成するためのスキームを設計した。
雄性Balb/Cマウス(およそ25g)(標準的住居、食餌/水への自由到達)は生理的食塩水2.3ml、もしくは800UのRNアーゼ阻害剤と一緒の短縮されたT7プロモーターのin vitro転写方法により調製されたマウスインスリン受容体に対し向けられたsiRNA(NCBI受託番号NM_010568;塩基2536−2556)40マイクログラムを含有する生理的食塩水のいずれかの尾静脈注入を受領した。
Claims (8)
- a)鋳型で伸長されたセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中で、標的特異的センスオリゴヌクレオチド鋳型およびT7 RNAポリメラーゼを組み合わせること;
b)鋳型で伸長されたアンチセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中で、標的特異的アンチセンスオリゴヌクレオチド鋳型およびT7 RNAポリメラーゼを組み合わせること;ならびに
c)段階a)で得られるセンスオリゴリボヌクレオチド産物を段階b)で得られる相補的アンチセンスオリゴリボヌクレオチド産物とハイブリダイズさせることであって、
段階a)およびb)のオリゴヌクレオチド鋳型が、鋳型鎖の5'端で標的特異的鋳型配列を伴い伸長された以下の図1
に示されるところの短縮されたT7 RNAポリメラーゼプロモーター配列よりなるRNAポリメラーゼプロモーター配列を含んで成り、ここで前記標的特異的鋳型配列が5'端に2個のグアノシン(g)ヌクレオチドおよび3'端に2個のシトシン(c)ヌクレオチドを含んで成る、
ことを特徴とする、
の段階を含んで成る、30ヌクレオチド長未満の標的特異的な短い二本鎖RNAの合成方法。 - 段階a)およびb)のオリゴヌクレオチド鋳型が、請求項1記載の図1に示されるところの二本鎖の短縮されたT7 RNAポリメラーゼプロモーター配列を含んで成る部分的に二本鎖のDNAオリゴ鋳型であることをさらに特徴とする、請求項1記載の方法。
- a)鋳型で伸長されたセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中で、センスsiRNA鋳型をT7 RNAポリメラーゼと組み合わせること;b)鋳型で伸長されたアンチセンスオリゴリボヌクレオチド産物が形成されるような反応混合物中で、アンチセンスsiRNA鋳型をT7 RNAポリメラーゼと組み合わせること;ならびに
c)段階a)で得られるセンスオリゴリボヌクレオチド産物を段階b)で得られるアンチセンスオリゴリボヌクレオチド産物とハイブリダイズさせること;
それにより、段階a)およびb)のsiRNA鋳型が、鋳型鎖の5'端で請求項1で定義されるところの標的特異的鋳型配列および2もしくは3個の付加的ヌクレオチドを伴い伸長された請求項1記載の図1に示されるところの短縮されたT7 RNAポリメラーゼプロモーター配列よりなる二本鎖RNAポリメラーゼプロモーター配列を含んで成る、
の段階を含んで成る、12〜30ヌクレオチドの低分子干渉RNA(siRNA)の合成方法。 - 短い二本鎖RNAがセンス配列5'−gg(n15-30)cc−3'[ここでgは(請求項1記載の図1に示されるところの)短縮されたT7 RNAポリメラーゼプロモーターから転写されたヌクレオチドグアノシンを指し、cは(請求項1記載の図1に示されるところの)短縮されたT7 RNAポリメラーゼプロモーター配列から転写されたヌクレオチドに相補的なヌクレオチドシトシンを指し、そしてn15-30は15ないし30ヌクレオチドのいずれかのオリゴヌクレオチドを指す]を有することを特徴とする標的特異的な短い二本鎖RNAを含んで成るRNAの、インビトロでの細胞中への導入を含んで成る、細胞中での標的遺伝子の発現の阻害方法。
- 標的特異的な短い二本鎖RNAが2もしくは3個の付加的ヌクレオチドを伴い3'端で伸長される、請求項4記載の方法。
- 標的遺伝子が、細胞遺伝子、内在性遺伝子、トランスジーンもしくは病原体からの遺伝子である、請求項4ないし5のいずれか1つ記載の方法。
- 請求項1ないし3のいずれか1つ記載の方法での使用のための反応混合物であって、
鋳型が、前記鋳型鎖の5'端で標的特異的鋳型配列を伴い伸長された請求項1記載の図1に示されるところの短縮されたT7 RNAポリメラーゼプロモーター配列よりなるRNAポリメラーゼプロモーター配列を含んで成り、ここで前記標的特異的鋳型配列は5'端に2個のグアノシン(g)ヌクレオチドおよび3'端に2個のシトシン(c)ヌクレオチドを含んで成ることを特徴とする、標的特異的センスオリゴヌクレオチド鋳型、および、
鋳型が、前記鋳型鎖の5'端で標的特異的鋳型配列を伴い伸長された請求項1記載の図1に示されるところの短縮されたT7 RNAポリメラーゼプロモーター配列よりなるRNAポリメラーゼプロモーター配列を含んで成り、ここで前記標的特異的鋳型配列は5'端に2個のグアノシン(g)ヌクレオチドおよび3'端に2個のシトシン(c)ヌクレオチドを含んで成ることを特徴とする、標的特異的アンチセンスオリゴヌクレオチド鋳型を含んでなる、
上記反応混合物。 - 標的特異的センスおよびアンチセンスオリゴヌクレオチド鋳型を設計するための方法であって、以下の段階;
1)標的遺伝子のコーディング配列内に配置されかつ以下の配列5'−xx(n12-30)yy−3'[式中xはプロモーターから転写されたヌクレオチドを指し、yはプロモーター配列から転写されたヌクレオチドに相補的なヌクレオチドを指し、そしてn12-30は12ないし30ヌクレオチドのいずれかのオリゴヌクレオチドを指す]を有する標的特異的配列を探す、
2)場合によっては2個の付加的なヌクレオチドを伴い伸長された、段階1)で配置された標的特異的配列の相補物オリゴヌクレオチド配列を伴い鋳型鎖の5'端で伸長された、本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るセンスオリゴヌクレオチド鋳型を設計する、
3)場合によっては2個の付加的なヌクレオチドを伴い伸長された、段階1)で配置された標的特異的配列の逆オリゴヌクレオチド配列を伴い鋳型鎖の5'端で伸長された、本発明の二本鎖RNAポリメラーゼプロモーター配列を含んで成るアンチセンスオリゴヌクレオチド鋳型を設計する、
を含んで成る上記方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33797501P | 2001-11-05 | 2001-11-05 | |
PCT/EP2002/012165 WO2003040294A2 (en) | 2001-11-05 | 2002-10-30 | METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005508177A JP2005508177A (ja) | 2005-03-31 |
JP4463554B2 true JP4463554B2 (ja) | 2010-05-19 |
Family
ID=23322851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003542541A Expired - Fee Related JP4463554B2 (ja) | 2001-11-05 | 2002-10-30 | 短い二本鎖RNAのinvitro合成方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7659391B2 (ja) |
EP (1) | EP1444347B1 (ja) |
JP (1) | JP4463554B2 (ja) |
KR (1) | KR20050041999A (ja) |
CN (1) | CN1318586C (ja) |
AT (1) | ATE310818T1 (ja) |
AU (1) | AU2002338926B2 (ja) |
CA (1) | CA2464626A1 (ja) |
DE (1) | DE60207601T2 (ja) |
ES (1) | ES2253565T3 (ja) |
IL (1) | IL161664A0 (ja) |
NO (1) | NO20042306L (ja) |
NZ (1) | NZ531803A (ja) |
WO (1) | WO2003040294A2 (ja) |
ZA (1) | ZA200403377B (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
ATE529512T1 (de) * | 2002-02-01 | 2011-11-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
GB0315401D0 (en) * | 2003-07-01 | 2003-08-06 | Roslin Inst Edinburgh | Disease resistant transgenic non-human animals |
NL1026335C2 (nl) * | 2004-06-04 | 2005-12-06 | Univ Delft Tech | Werkwijze voor het maken van een dubbelstrengs polyribonucleotidenvolgorde met overhangend uiteinde, alsmede een werkwijze voor het vormen van een dubbelstrengs polynucleotidenconstruct en een toepassing. |
EP1819365B1 (en) * | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
US20060142228A1 (en) | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
WO2006081623A1 (en) * | 2005-02-04 | 2006-08-10 | The Australian National University | Double-stranded oligonucleotides and uses therefor |
US8999943B2 (en) * | 2005-03-14 | 2015-04-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
EP2325315B1 (en) * | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
EP2641970B1 (en) | 2005-11-17 | 2014-12-24 | Board of Regents, The University of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
DE102007000226A1 (de) * | 2007-04-13 | 2008-10-16 | Hilti Aktiengesellschaft | Handgeführtes Eintreibgerät |
CN101914540A (zh) * | 2010-08-09 | 2010-12-15 | 大连大学 | 一种将rna干扰引入植物的方法 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014152027A1 (en) * | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
JP2017522028A (ja) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 環状ポリヌクレオチド |
AU2016324463B2 (en) | 2015-09-17 | 2022-10-27 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
JP2020510426A (ja) | 2017-02-28 | 2020-04-09 | アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. | 翻訳可能分子およびその合成 |
US20210040472A1 (en) | 2019-08-09 | 2021-02-11 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
CN112626152A (zh) * | 2020-12-18 | 2021-04-09 | 深圳大学 | siRNA的制备方法 |
CN113943764B (zh) * | 2021-12-20 | 2022-03-04 | 中国海洋大学 | 一种制备双链rna的方法 |
CN115807048B (zh) * | 2022-07-19 | 2024-03-22 | 中国海洋大学 | 一种制备双链rna的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614403A (en) * | 1994-06-01 | 1997-03-25 | Baylor College Of Medicine | In vitro replication system capable of rescuing cloned and manipulated rotavirus genes |
US6214546B1 (en) * | 1995-02-27 | 2001-04-10 | Intelligene Ltd. | Detection of biomolecules |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU781598B2 (en) | 1999-04-21 | 2005-06-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2001029058A1 (en) * | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
DK1309726T4 (en) * | 2000-03-30 | 2019-01-28 | Whitehead Inst Biomedical Res | RNA Sequence-Specific Mediators of RNA Interference |
US6958217B2 (en) * | 2001-01-24 | 2005-10-25 | Genomic Expression Aps | Single-stranded polynucleotide tags |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
-
2002
- 2002-10-30 AT AT02777337T patent/ATE310818T1/de not_active IP Right Cessation
- 2002-10-30 CN CNB028220986A patent/CN1318586C/zh not_active Expired - Fee Related
- 2002-10-30 US US10/494,663 patent/US7659391B2/en not_active Expired - Fee Related
- 2002-10-30 CA CA002464626A patent/CA2464626A1/en not_active Abandoned
- 2002-10-30 KR KR1020047004983A patent/KR20050041999A/ko not_active Application Discontinuation
- 2002-10-30 IL IL16166402A patent/IL161664A0/xx unknown
- 2002-10-30 ES ES02777337T patent/ES2253565T3/es not_active Expired - Lifetime
- 2002-10-30 WO PCT/EP2002/012165 patent/WO2003040294A2/en active IP Right Grant
- 2002-10-30 JP JP2003542541A patent/JP4463554B2/ja not_active Expired - Fee Related
- 2002-10-30 NZ NZ531803A patent/NZ531803A/en unknown
- 2002-10-30 EP EP02777337A patent/EP1444347B1/en not_active Expired - Lifetime
- 2002-10-30 AU AU2002338926A patent/AU2002338926B2/en not_active Expired - Fee Related
- 2002-10-30 DE DE60207601T patent/DE60207601T2/de not_active Expired - Lifetime
-
2004
- 2004-05-04 ZA ZA200403377A patent/ZA200403377B/en unknown
- 2004-06-03 NO NO20042306A patent/NO20042306L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE60207601T2 (de) | 2006-08-17 |
WO2003040294A3 (en) | 2003-12-24 |
AU2002338926B2 (en) | 2007-05-24 |
NZ531803A (en) | 2006-09-29 |
EP1444347B1 (en) | 2005-11-23 |
KR20050041999A (ko) | 2005-05-04 |
US7659391B2 (en) | 2010-02-09 |
NO20042306L (no) | 2004-08-03 |
DE60207601D1 (de) | 2005-12-29 |
ES2253565T3 (es) | 2006-06-01 |
CN1604963A (zh) | 2005-04-06 |
CA2464626A1 (en) | 2003-05-15 |
JP2005508177A (ja) | 2005-03-31 |
US20040259097A1 (en) | 2004-12-23 |
WO2003040294A2 (en) | 2003-05-15 |
IL161664A0 (en) | 2004-09-27 |
ATE310818T1 (de) | 2005-12-15 |
ZA200403377B (en) | 2005-05-04 |
EP1444347A2 (en) | 2004-08-11 |
CN1318586C (zh) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4463554B2 (ja) | 短い二本鎖RNAのinvitro合成方法 | |
AU2002338926A1 (en) | Method for the in vitro synthesis of short double stranded RNAs | |
EP2143792B1 (en) | Single-stranded cyclic RNA, and method of production thereof | |
EP1552018B1 (en) | Methods and compositions relating to gene silencing | |
EP2222848B1 (en) | Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof | |
KR20060029597A (ko) | Rna 간섭에 기반한 hbv 유전자 발현의 억제 방법 및조성물 | |
CN116121246A (zh) | 一种新型小激活rna | |
US20080207539A1 (en) | Self-Processing Rna Expression Cassette | |
WO2006130976A1 (en) | Interfering rnas, methods for their production, and use | |
CN116981773A (zh) | 用于编辑靶标rna的多聚腺苷酸化信号序列的指导rna | |
US9540644B2 (en) | Small interference RNA for inhibiting intracellular expression of ribosomal protein S3 | |
US20040086860A1 (en) | Methods of producing RNAs of defined length and sequence | |
KR100385905B1 (ko) | 유니진 유래의 안티센스 분자로 구성된 안티센스 라이브러리를 이용한 대규모 유전자 검색 및 기능 분석 방법 | |
Karkare et al. | RNA interference silencing the transcriptional message: aspects and applications | |
EP1644499B1 (en) | siRNA EXPRESSION SYSTEM | |
Jiang et al. | shRNA inhibits the expression of chicken telomerase reverse transcriptase in MDCC-MSB1 cells | |
CN117247932A (zh) | 一种提高体外转录中帽子类似物利用率的方法 | |
JP2005006578A (ja) | イン・ビトロ転写反応を利用した機能性rna分子の製造方法 | |
KR20090106425A (ko) | 마이크로rna 생성을 억제하는 드로셔 돌연변이 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051006 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100209 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100217 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130226 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4463554 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130226 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140226 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |